1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Maxinovel Pharmaceuticals

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2016

Location

Guangzhou Guangdong China

Primary Industry

Pharmaceuticals

About

Established in 2016 and based in Guangzhou, China, Zaiji Medicine is a medical company that focuses on the research and development of small molecule targeted drugs and tumor immune drugs. The management and technical teams have over 20 years of experience in drug discovery and clinical management. The company has established R&D and operation centers in Shanghai, Guangzhou and Shenzhen. And, we also have offices in the United States and Australia. In April 2018, this company received orphan drug status from the U.S. Food and Drug Administration (FDA) for its clinical product Max-40279. The company's co-founder, Chairman and President, Yuguang Wang, graduated from the University of Kansas with over 30 years of experience in new drug development and management, and was the recipient of the 2008 Edison Patent Award for invention. The company's main business is the research and development of acute myeloid leukemia, colorectal cancer, gastric cancer, lung cancer and other fields, products involving tumor targeting, tumor immunity, skin drugs and other innovative drugs. Their self-developed products such as acute myeloid leukemia drug MAX-4, solid tumor targeted therapy drug MAX-5, baldness hair drug MAX-3 and radioligand therapy drug MAX-8.
Current Investors
Share Capital, Ruimeng Venture Capital, Zhongguancun Venture Capital

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.maxinovel.com
Company Stage
Series C
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.